or the time from first conventional therapy to biologic therapy initiation in patients with psoriasis. Previous use of conventional systemic therapy does not significantly impact subsequent biologic ...

Psoriasis, in its most severe presentation, is a candidate for biologic and biosimilar medications. These medications represent “stage 3” treatments for situations where topical, phototherapy ...

Opens in a new tab or window Researchers have designed a new resource for prescribing biologics to patients with psoriasis. The report covers TNF-α inhibitors, as well as IL-12, IL-17 ...

Flakes won’t go away? You might be dealing with scalp psoriasis instead of dandruff! Here's how to know the difference ...

The global psoriasis therapeutics market revenue was around US$ 25.0 billion in 2022 and is estimated to reach US$ 55.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.3% during ...

Are you suffering from nail psoriasis? Look out for these warning and most unusual signs of the condition, and understand how ...

Prof. Adam Reich reviewed itch in psoriasis, while Dr. Anushka Irani discussed the connection between pain and psoriatic ...

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

The company, AndHealth, aims to prove its unique approach can slow or even reverse the progression of some chronic diseases ...

Pursuant to the terms of the securities purchase agreement, Oruka is selling an aggregate of (i) 5,600,000 shares of its common stock (“Common Stock”) at a purchase price of $23.00 per share, (ii) ...

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

Johnson & Johnson (JNJ) said that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab) for the treatment of adults ...